Cate Lockhart, PharmD, PhD: Biosimilars and Price Competition
Cate Lockhart, PharmD, PhD, discusses when she believes the industry will start seeing biosimilars driving down cost of drugs.
Cate Lockhart, PharmD, PhD: Similarities Between Biosimilars and Generics
Cate Lockhart, PharmD, PhD, explains the similarities and differences between generics and biosimilars.
Sheila Frame: What Excites Sandoz About Biosimilars
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, explains what about biosimilars excites the company.
Sheila Frame: Adoption of Biosimilars
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses how physicians' attitudes toward biosimilars have changed.
Mark Cziraky, PharmD, CLS: Payers' Decisions on Biosimilars
Mark Cziraky, PharmD, CLS, explains the role of health economics and outcomes research in a payer’s decision to potentially adopt a biosimilar.
Sheila Frame: Switching to a Biosimilar
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses patient concerns about switching to a biosimilar.
Sheila Frame: The BPCIA's Impact on Industry
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, explains how the Biologics Price Competition and Innovation Act (BPCIA) has impacted the industry.
Mark Cziraky, PharmD, CLS: Biosimilars and Real-World Data
Mark Cziraky, PharmD, CLS, explains why real-world data are key in the biosimilars marketplace.
Sheila Frame: Biosimilars and the Policy Environment
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses policy challenges related to biosimilars.
Sheila Frame: Biosimilars and Device Design
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses the importance of device design for biosimilars.
Mark Cziraky, PharmD, CLS: Biosimilar Utilization
Mark Cziraky, PharmD, CLS, vice president of research for Healthcore, explains why biosimilar utilization in the United States is low.
Mark Cziraky, PharmD, CLS: Challenges in the US Biosimilars Market
Mark Cziraky, PharmD, CLS, vice president of research for Healthcore, describes challenges in the US biosimilars market.
Sheila Frame: Biosimilars and Cost Reductions for Patients
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses when patients will see their costs reduced as a result of biosimilars.
Sheila Frame: Biosimilars and Patient Access
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses how biosimilars can increase patient access to treatment.
Tahir Amin: Reforming the Patent System
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses reforming the patent system.
Tahir Amin: Lessons Learned from Allergan's Patent Transfer
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses lessons learned from Allergan's transfer of patents to a sovereign tribe.
Sal Patel, JD: How Sandoz v Amgen Changed the Biosimilars Landscape
Sal Patel, JD, partner at Schiff Hardin, LLP, explains how the Supreme Court's 2017 ruling in Sandoz v Amgen changed the biosimilars landscape.
Sal Patel, JD: Settlements That End Patent Litigation
Sal Patel, JD, partner at Schiff Hardin, LLP, explains why he expects to see more settlements between drug manufacturers in the future.
Sheila Frame: Therapeutic Areas That Need Biosimilars
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses which therapeutic areas need biosimilars the most.
Sheila Frame: Differences Between the US and European Biosimilars Markets
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, addresses key differences between the US market and the EU market for biosimilars.
Sal Patel, JD: Ongoing BPCIA Litigations
Sal Patel, JD, partner at Schiff Hardin, LLP, explains why he is watching litigations concerning rheumatoid arthritis drugs closely.
Imron Aly, JD: Hatch-Waxman and BPCIA Litigation
Imron Aly, JD, partner at Schiff Hardin, LLP, explains how lessons learned from Hatch-Waxman proceedings can be applied to Biologics Price Competition and Innovation Act (BPCIA) litigation.
Sheila Frame: The Manufacturer's Challenges in Getting Biosimilars to Market
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses the challenges that biosimilar developers face in getting their products to market.
Sheila Frame: Lessons Learned From Launching Zarxio
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses lessons learned from the launch of the company’s biosimilar filgrastim.
Louis Tharp: Drivers of High Drug Costs
Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses what drives high drug costs in the United States.
Louis Tharp: The Burden of High-Cost Biologics
Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses the burden of high-cost biologics for patients with rheumatic diseases.
Tahir Amin: Successful Challenges to Drug Patents
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses successes in drug patent challenges.
Tahir Amin: Drug Patents and Innovation
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses the link between drug patents and innovation.
Anne Bass, MD: Thromboembolic Events in Patients With Rheumatic Disease
Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, explains why patients with rheumatic diseases are at risk for thromboembolism.
Anne Bass, MD: Screening for Tuberculosis Before Starting Biologics
Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, explains why screening patients for tuberculosis before initiating biologic therapy is key.